Lam CSP, Ramasundarahettige C, Branch KRH, et al. - Efpeglenatide’s safety and efficacy appear independent of concurrent sodium-glucose co-transporter-2 (SGLT2) inhibitor use. Combined SGLT2 inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment in type 2 diabetes is supported.

• Given that once weekly injections of the GLP-1 RA efpeglenatide (vs placebo) decreased major adverse cardiovascular events (MACE); MACE, coronary revascularization or unstable angina hospitalization (expanded MACE); a renal composite outcome; and MACE or death in individuals with type 2 diabetes and CV and/or renal disease, in the AMPLITUDE-O trial.

• Herein, the integrated impact of SGLT2 inhibitors and efpeglenatide on clinical results were examined.

• The impact (hazard ratio) of efpeglenatide compared with placebo in the absence and presence of baseline SGLT2 inhibitors, respectively, on MACE (0.74 and 0.70), expanded MACE (0.77 and 0.87), renal composite (0.70 and 0.52), and MACE or death (0.74 and 0.65) was not different by baseline SGLT2 inhibitor use.

• Decrease in blood pressure, body weight, low density lipoprotein cholesterol and urinary albumin:creatinine ratio was brought about by efpeglenatide and such impact also seemed to be independent of concurrent SGLT2 inhibitor use.

• Based on baseline SGLT2 inhibitor use, there was no difference in adverse events.